Hikma Pharmaceuticals (OTCMKTS:HKMPF) Shares Gap Up – Still a Buy?

Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF)’s stock price gapped up before the market opened on Wednesday . The stock had previously closed at $20.9205, but opened at $22.5550. Hikma Pharmaceuticals shares last traded at $22.2950, with a volume of 550 shares.

Analysts Set New Price Targets

Separately, Barclays cut shares of Hikma Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Tuesday, January 6th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold”.

Hikma Pharmaceuticals Stock Performance

The stock has a 50 day moving average price of $20.66 and a two-hundred day moving average price of $22.63. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.72 and a current ratio of 1.24.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals is a multinational pharmaceutical company that develops, manufactures and markets a broad range of branded and non-branded generics, specialty injectables and consumer healthcare products. The company’s three core business segments include generic medicines, injectable products and branded generics, serving hospitals, wholesalers and pharmacies worldwide. Its product portfolio spans diverse therapeutic areas such as cardiovascular, oncology, respiratory, pain management and anti-infectives, with an emphasis on injectable solutions for complex hospital treatments.

Founded in 1978 in Amman, Jordan, Hikma has grown through organic expansion and strategic acquisitions to become one of the leading pharmaceutical players in the Middle East, North Africa, Europe and the United States.